<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427386</url>
  </required_header>
  <id_info>
    <org_study_id>FMUSP</org_study_id>
    <nct_id>NCT02427386</nct_id>
  </id_info>
  <brief_title>Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis</brief_title>
  <official_title>Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometriosis is a chronic inflammatory disease that causes pelvic pain difficult to treat.
      In view of this, many patients seek assistance in complementary and alternative medicine,
      including homeopathic treatment. The absence of evidence in the literature raises controversy
      about the effectiveness of homeopathic treatment in endometriosis. The aim of this randomized
      trial is to evaluate the effectiveness of dynamized estrogen compared to placebo in the
      treatment of chronic pelvic pain of endometriosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind and placebo controlled trial using individualised
      homeopathic medicine (dynamized estrogen) to treat chronic pelvic pain of endometriosis.
      Patients with endometriosis, chronic pelvic pain and a set of signs and symptoms similar to
      those of the estrogen adverse events will be recruited in the Sector of Endometriosis of the
      Clinical Division of Gynaecological of the Hospital das Clínicas of the Faculty of Medicine
      of the University of Sao Paulo. The selection process was carried out through the analysis of
      medical charts and self-completing of structured questionnaires. Satisfied the inclusion
      criteria, fifty patients were randomly and distributed to receive dynamized estrogen or
      placebo. The primary clinical outcome is the severity of the chronic pelvic pain. Statistical
      analysis will be by intention-to-treat and per protocol comparing homeopathic drug with
      placebo after 24 weeks of intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chronic pelvic pain (measured by visual analog scale (VAS-Pain)</measure>
    <time_frame>24 weeks (6 months)</time_frame>
    <description>chronic pelvic pain (dysmenorrhoea, dyspareunia, acyclic pelvic pain depth, cyclic intestinal change and cyclic urinary change) measured by visual analog scale (VAS-Pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36)</measure>
    <time_frame>24 weeks (6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Endometriosis</condition>
  <condition>Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>dynamized estrogen in alcohol solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (alcohol solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm received alcohol solution during the 24-week study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dynamized estrogen</intervention_name>
    <description>The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).</description>
    <arm_group_label>dynamized estrogen in alcohol solution</arm_group_label>
    <other_name>dynamized 17-beta estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.</description>
    <arm_group_label>placebo (alcohol solution)</arm_group_label>
    <other_name>alcohol solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        primary inclusion criteria:

          -  aged between 18 and 45;

          -  diagnosis of endometriosis (endometrial ectopia) confirmed by imaging test (MRI or
             TVUS) or laparoscopy (biopsy);

          -  chronic pelvic pain refractory to conventional hormone treatments and with intensity ≥
             5 on the visual analog pain scale (VAS-Pain: 0-10 points);

        secondary inclusion criteria:

          -  symptomatic individualization of patients according to adverse events of estrogen
             (minimum syndrome of maximum value).

        Exclusion Criteria:

          -  absence of clinical and laboratory diagnosis of menopause or

          -  premature ovarian failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Z Teixeira, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo General Hospital</affiliation>
  </overall_official>
  <link>
    <url>http://www.newhomeopathicmedicines.com</url>
    <description>New homeopathic medicines: use of modern drugs according to the principle of similitude</description>
  </link>
  <reference>
    <citation>Teixeira MZ. 'New Homeopathic Medicines' database: A project to employ conventional drugs according to the homeopathic method of treatment. European Journal of Integrative Medicine 5(3): 270-278, 2013.</citation>
  </reference>
  <reference>
    <citation>Teixeira MZ, Podgaec S, Baracat EC. Protocol of randomized controlled trial of potentized estrogen in homeopathic treatment of chronic pelvic pain associated with endometriosis. Homeopathy. 2016 Aug;105(3):240-249. doi: 10.1016/j.homp.2016.03.002. Epub 2016 May 13.</citation>
    <PMID>27473545</PMID>
  </reference>
  <reference>
    <citation>Teixeira MZ, Podgaec S, Baracat EC. Potentized estrogen in homeopathic treatment of endometriosis-associated pelvic pain: A 24-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2017 Apr;211:48-55. doi: 10.1016/j.ejogrb.2017.01.052. Epub 2017 Jan 25.</citation>
    <PMID>28187404</PMID>
  </reference>
  <results_reference>
    <citation>Teixeira MZ. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses. 2003 Feb;60(2):276-83.</citation>
    <PMID>12606247</PMID>
  </results_reference>
  <results_reference>
    <citation>Teixeira MZ. New homeopathic medicines: use of modern drugs according to the principle of similitude. Homeopathy. 2011 Oct;100(4):244-52. doi: 10.1016/j.homp.2011.01.002.</citation>
    <PMID>21962199</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Marcus Zulian Teixeira</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Pelvic pain</keyword>
  <keyword>Homeopathy</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

